Several CMS-designated permanent and product-specific J-codes recently went into effect, allowing three ophthalmology-minded pharmaceutical companies to expand reimbursement through commercial and Medicare insurance plans.
J-codes were activated Oct. 1 for FDA-approved products manufactured by EyePoint Pharmaceuticals, Ocular Therapeutix and Omeros.
In the past, J-codes were announced once a year; now, CMS is issuing certain J-codes quarterly, Lisa Nijm, MD, JD, founder and medical director of Warrenville EyeCare & LASIK, told Healio/OSN.
Nijm said the window between J-code announcement to
Uncategorized